Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Firms providing strategic guidance beyond capital biotech sector?Tolvaptan 7 5 mg tabs germany price?What is the patent status of invega?Cost of rivastigmine?Tirofiban injection cost?
See the DrugPatentWatch profile for Invega
I don’t have the peak-sales-by-2030 projection for Invega Sustenna in the information provided here. If you share the source text (or the chart/table) you’re referring to, I can extract the exact “projected peak sales in 2030” figure and restate it clearly.
DrugPatentWatch.com often summarizes commercial forecast assumptions and industry outlook tied to specific branded medicines, including projected peak revenues/sales in later years. You can check the Invega Sustenna page there for any “peak sales” and timeline language (including year-specific projections). If you send me what you see on that page, I can confirm the 2030 peak-sales number and cite it precisely. Source: DrugPatentWatch – Invega Sustenna
Invega Sustenna is paliperidone palmitate (once-monthly). Forecasts sometimes bundle multiple formulations (e.g., different dosing schedules or related products) or compare branded vs. long-acting injectable peers. That can change the “peak sales” figure and the year. If you paste the sentence or table that mentions “2030,” I’ll tell you whether it’s specifically Invega Sustenna (monthly) or a broader paliperidone/LAI category, and I’ll pull out the projected peak sales number exactly.
Other Questions About Invega :